Market Value: chemomab.com (CMMB)

Chemomab Therapeutics - graphic logo of issuer CMMB

The price chart for Chemomab Therapeutics (CMMB) helps illustrate the business's independence from economic cycles, as biotech success depends on patents. Current market capitalization stands at 0.01. Returns are driven by the development of antibodies targeting inflammation and organ fibrosis. Growth is based on proprietary scientific research and the pursuit of strategic partners to bring innovative drugs to market.

Chemomab Therapeutics Ltd - CMMB Market Value (period 07/04/2022 - 11/14/2026)

Financial and market metric breakdowns for Chemomab Therapeutics Ltd. (CMMB)

- market price and analyst price targets:
Price Chart Chemomab Therapeutics|CMMB - Consensus Target
- company stock exchange capitalization indicators:
Market Value Chemomab Therapeutics Ltd|CMMB - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Value per Share Chemomab Therapeutics|CMMB - Company Book Value|Market Value to Book Value Ratio chemomab.com|CMMB - Company Total Asset Base
- debt level and financial liquidity data:
Debt to Equity Chemomab Therapeutics|CMMB - Long-Term Liabilities to Equity|Short-Term Debt to Capital Chemomab Therapeutics Ltd.|CMMB - Company Cumulative Debt|Debts to Book Capitalization Chemomab Therapeutics Ltd|CMMB - Company Long-Term Liabilities|Company Short-Term Debts Chemomab Therapeutics|Quick Ratio chemomab.com
- financial results and valuation multiples details:
CMMB - Net Profit|Expected Profit Chemomab Therapeutics|CMMB - Price to Earnings Ratio|Forward P/E Multiple chemomab.com|CMMB - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Chemomab Therapeutics|CMMB - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Chemomab Therapeutics|CMMB - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth chemomab.com|CMMB - Earnings per share growth this year|Expected earnings per share growth for next year Chemomab Therapeutics
- sales revenue and business income indicators:
CMMB - Company Sales Revenue|Company Projected Revenue Chemomab Therapeutics Ltd|CMMB - Price-to-Sales Ratio|Forward P/S Multiple Chemomab Therapeutics Ltd
Initial company analysis:Chemomab Therapeutics Ltd. CMMB
Original product of chemomab.com

Investors utilize multiples to verify the financial stability of an issuer. Market capitalization represents the product of the current share price and the number of shares outstanding. By analyzing the company's market value, one can assess the dynamics of the asset's global liquidity. For Chemomab Therapeutics (CMMB), this indicator reflects market optimism against a backdrop of high clinical trial costs. The risks of failure in antibody development render this metric extremely volatile.

Competitors of Chemomab Therapeutics (CMMB)

Market Value Vertex Pharmaceuticals Inc. VRTX|Alnylam Corp - Market Value|INSM - Market Value|Market Value UTHR (unither.com)|BioMarin Pharma (BMRN) - Market Value|Market Value BridgeBio Pharma (BBIO)|Market Value BGM Group Corp|Cogent Corp (COGT) - Market Capitalization|Market Value Xeris Biopharma Inc (XERS)|KROS: Market Valuation|Market Capitalization ARCT (Arcturus Corp)|Eton Pharmaceuticals, Inc. (ETON) - Market Value|Kamada Pharma - Market Capitalization|Fulcrum Tx (FULC) - Market Valuation|ABEO: Market Capitalization|MREO - Market Capitalization|Market Value Protalix BioTherapeutics, Inc.|Market Capitalization pliantrx.com|Market Value Applied Therapeutics, Inc. (APLT)|Market Value RNTX (Rein Therapeutics, Inc.)|Market Capitalization GELS (gelteq.com)|Market Capitalization aytubio.com (AYTU)|SRXH: Market Valuation|Market Valuation PLRZ|AEZS: Market Capitalization|Market Value CTD Holdings (CYTH)|INZY (Inozyme Pharma) - Market Capitalization|Market Capitalization RPHM (Reneo Pharmaceuticals, Inc.)|Market Valuation CSCI (COSCIENS Biopharma)